Soligenix Inc. will collaborate with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation to recruit patients for its phase III clinical study of SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
